Department of Pediatrics, Bellinzona and Mendrisio Hospitals, University of Bern, Bern, Switzerland.
Pediatr Nephrol. 2010 Feb;25(2):205-12. doi: 10.1007/s00467-009-1253-3. Epub 2009 Jul 30.
Immunoglobulin (Ig)G antineutrophil cytoplasmic autoantibodies are causally associated with necrotizing vasculitides that are characterized immunopathologically by little or no deposition of immunoreactants, such as Wegener granulomatosis, microscopic polyangiitis, Churg-Strauss angiitis, "renal-limited" vasculitis and a number of drug-induced vasculitides. Clinical routine testing targets the antigens myeloperoxidase and proteinase 3. However, in all of the conditions mentioned, the renal histopathologic findings are indistinguishable. Churg-Strauss angiitis (characterized by necrotizing vasculitis, granulomatous inflammation and tissue eosinophilia), Wegener granulomatosis (characterized by necrotizing vasculitis and granulomatous inflammation) and microscopic polyangiitis (characterized by necrotizing vasculitis) often present with fever, weight loss and a multisystem involvement (ear, nose, throat, lung, eyes, peripheral nerve and heart). Fifty years ago these conditions were very often fatal within 6 months of diagnosis. The introduction of corticosteroids and cyclophosphamide has resulted in a dramatic clinical benefit. Patients who develop treatment-related morbidity can be switched from cyclophosphamide to azathioprine after achieving remission. In patients with less severe disease, methotrexate achieves remission with a success rate similar to that of cyclophosphamide. Plasma exchange, in association with immunosuppression, is likely to be a beneficial therapy for patients with severe kidney disease or pulmonary hemorrhage.
免疫球蛋白(Ig)G 抗中性粒细胞胞质自身抗体与坏死性血管炎有关,这些血管炎在免疫病理学上的特征是很少或没有免疫反应物沉积,如韦格纳肉芽肿、显微镜下多血管炎、变应性肉芽肿性血管炎、“肾限性”血管炎和许多药物诱导的血管炎。临床常规检测的靶抗原是髓过氧化物酶和蛋白酶 3。然而,在提到的所有情况下,肾脏组织病理学发现都是无法区分的。变应性肉芽肿性血管炎(以坏死性血管炎、肉芽肿性炎症和组织嗜酸性粒细胞增多为特征)、韦格纳肉芽肿(以坏死性血管炎和肉芽肿性炎症为特征)和显微镜下多血管炎(以坏死性血管炎为特征)常伴有发热、体重减轻和多系统受累(耳、鼻、喉、肺、眼、周围神经和心脏)。五十年前,这些疾病在诊断后 6 个月内常常致命。皮质类固醇和环磷酰胺的引入带来了显著的临床获益。在达到缓解后,那些出现与治疗相关的发病率的患者可以从环磷酰胺转换为硫唑嘌呤。在病情较轻的患者中,甲氨蝶呤的缓解率与环磷酰胺相似。血浆置换与免疫抑制联合使用,可能对患有严重肾脏疾病或肺出血的患者有益。